Navann Ty
Stock Analyst at Exane BNP Paribas
(2.82)
# 1,566
Out of 5,182 analysts
26
Total ratings
64.29%
Success rate
26.02%
Average return
Main Sectors:
Stocks Rated by Navann Ty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KVUE Kenvue | Initiates: Neutral | $28 | $17.20 | +62.79% | 1 | May 30, 2023 | |
| ALKS Alkermes | Maintains: Neutral | $22 → $26 | $33.85 | -23.19% | 10 | Mar 22, 2022 | |
| VTRS Viatris | Maintains: Neutral | $16 → $11 | $15.02 | -26.76% | 2 | Mar 10, 2022 | |
| ZTS Zoetis | Maintains: Neutral | $184 → $232 | $114.18 | +103.20% | 4 | Dec 20, 2021 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $200 | $200.37 | -0.18% | 7 | Oct 5, 2021 | |
| OGN Organon & Co. | Initiates: Buy | $35 | $13.32 | +162.86% | 2 | Jul 23, 2021 |
Kenvue
May 30, 2023
Initiates: Neutral
Price Target: $28
Current: $17.20
Upside: +62.79%
Alkermes
Mar 22, 2022
Maintains: Neutral
Price Target: $22 → $26
Current: $33.85
Upside: -23.19%
Viatris
Mar 10, 2022
Maintains: Neutral
Price Target: $16 → $11
Current: $15.02
Upside: -26.76%
Zoetis
Dec 20, 2021
Maintains: Neutral
Price Target: $184 → $232
Current: $114.18
Upside: +103.20%
Jazz Pharmaceuticals
Oct 5, 2021
Initiates: Buy
Price Target: $200
Current: $200.37
Upside: -0.18%
Organon & Co.
Jul 23, 2021
Initiates: Buy
Price Target: $35
Current: $13.32
Upside: +162.86%